Maintenance Drug Treatment for Schizophrenia
John G. Csernansky
Department of Psychiatry (Box 8134)
Washington Univ. School of Medicine
4940 Children's Place
St. Louis, Missouri 63105
Phone: (314) 362-2616
Fax: (314) 362-2099
csernanj@medicine.wustl.edu
REFERENCES
1. Adan F, Siris SG. Trials of adjunctive alprazolam in "negative symptom" patients. Can J Psychiatry 1989;34:326-328.
2. Adler LA, Angrist B, Reiter S, Rotrosen J. Neuroleptic-induced akathisia: a review. Psychopharmacology 1989;97:1-11.
3. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. A J Psychiatry 1997;154(April Supplement).
4. Angrist B, Rotrosen J, Gershon S. Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia. Psychopharmacology 1980;72:17-19.
5. Arvanitis L, Miller BG, Seroquel Trial 13 Study Group. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233-246.
6. Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988;45:79-91.
7. Bellack AS, Turner SM, Hersen M, Luber RF. An examination of the efficacy of social skills training for chronic schizophrenic patients. Hosp Comm Psychiatry 1984;35:1023-1028.
8. Braude WM, Barnes TRE, Gore SM. Clinical characteristics of akathisia. Br J Psychiatry 1983;143:134-150.
9. Breier A, Buchanan RW, Kirkpatrick B, et al. Clozapine in schizophrenic outpatients: Efficacy, long-term outcome, and relationship to prefrontal cortex. Schizophrenia Res 1993;9:257-258.
10. Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry 1998;155:751-760.
11. Buchanan RW, Holstein C, Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry 1994;36:717-725.
12. Buchanan RW, Kirkpatrick B, Summerfelt A, Hanlon TE, Levine J, Carpenter WT Jr. Clinical predictors of relapse following neuroleptic withdrawal. Biol Psychiary 1992;32:72-78.
13. Carpenter WT Jr, Hanlon TE, Heinrichs DW, et al. Continuous versus targeted medication in schizophrenic outpatients: Outcome results. Am J Psychiatry 1990;147:1138-1148.
14. Carpenter WT Jr, Heinrichs DW, Wagman AM. Deficit and nondeficit forms of schizophrenia: The concept. Am J Psychiatry 1988;145:578-583.
15. Carpenter WT Jr, Heinrichs DW, Hanlon TE. A comparative trial of pharmacologic strategies in schizophrenia. Am J Psychiatry 1987;144:1466-1470.
16. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40.
17. Claghorn J, Honigfeld G, Abuzzahab F, et al. The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 1987;7:377-384.
18. Claus A, Bollen J, De Cuyper H, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: A multi-center double-blind comparative study. Acta Psychiatr Scand 1992;85:295-305.
19. Csernansky JG, Lombrozo L, Gulevich GD, Hollister LE. Treatment of negative schizophrenic symptoms with alprazolam: A preliminary open-label study. J Clin Psychopharmacol 1984;4:349-352.
20. Csernansky JG, Riney SJ, Lombrozo L, Overall JE, Hollister LE. Double-blind comparison of alprazolam, diazepam and placebo for the treatment of negative schizophrenic symptoms. Arch Gen Psychiatry 1988;45:655-659.
21. Davis JM. Maintenance therapy and the natural course of schizophrenia. J Clin Psychiatry 1985;11:18-21.
22. Dellva MA, Tran P, Tollefson GD, Wentley AL, Beasley CM Jr.Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. Psychiatric Services 1997;48:1571-1577.
23. Drake RE, Erhlich J. Suicide attempts associated with akathisia. Am J Psychiatry 1985;142:499-501.
24. Eckman TA, Liberman RP, Phipps CC, Blair KE. Teaching medication management skills to schizophrenic patients. J Clin Psychopharmacol 1990;10:33-38.
25. Falloon IRH, Boyd JL, McGill CW, et al. Family management in the prevention of morbidity of schizophrenia. Clinical outcome of a two-year longitudinal study. Arch Gen Psychiatry 1985;42:887-896.
26. Faraone SV, Brown WA, Laughren TP. Serum neuroleptic levels, prolactin levels, and relapse: A two-year study of schizophrenic outpatients. J Clin Psychiatry 1987;48:151-154.
27. Farde L, Nordstrom A-L, Wiesel F-A, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49:538-544.
28. Faustman WO, Hoff AL. Effects of antipsychotic drugs on neuropsychological measures. In: Csernansky JG, ed., Antipsychotics (Handbook of Experimental Pharmacology, Volume 120) Berlin: Springer-Verlag, 1996;445-478 .
29. Friis T, Christensen TR, Gerlach J. Sodium valproate and biperiden in neuroleptic-induced akathisia, parkinsonism and hyperkinesia: a double-blind cross-over study with placebo. Acta Psychiatr Scand 1982;67:178-187.
30. Glazer WM, Bowers MB Jr, Charney DS, Heninger GR. The effect of neuroleptic discontinuation on psychopathology, involuntary movements, and biochemical measures in patients with persistent tardive dyskinesia. Biol Psychiatry 1989;26:224-233.
31. Green MF. What are the consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996;153:321-330.
32. Green MF, Marshall BD, Wirshing WC, et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 1997;154:799-804.
33. Goldberg SC. Negative and deficit symptoms in schizophrenia do respond to neuroleptics. Schizophrenia Bull 1985;11:453-456.
34. Hagger C, Buckley P, Kenny JT, et al. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patietns receiving clozapine. Biol Psych 1993;34:702-712.
35. Hamilton SH, Revicki DA, Genduso LA, Beasley CM Jr. Olanzapine versus placebo and haloperidol: Quality of life and efficacy results of the North American double-blind trial. Neuropsychopharmacol 1998;18:41-49.
36. Herz MI, Lamberti JS, Schwarzkopf SB, Crilly JF. Prodromal symptoms in schizophrenia: A prospective study and review. Schizophrenia Res 1993;9:266.
37. Herz MI, Melville C. Relapse in schizophrenia. Am J Psychiatry 1980;137:801-805.
38. Herz MI, Szymanski HV, Simon JC. Intermittent medication for stable schizophrenic outpatients: An alternative to maintenance mediation. Am J Psychiatry 1982;139:918-922.
39. Hoff AL, Faustman WO, Wiencke M, et al. The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients. Neuropsychopharmacol 1996;15:361-369.
40. Hogarty GE, Anderson CM, Reiss DJ, et al. Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia. II. Two-year effects of a controlled study on relapse and adjustment. Arch Gen Psychiatry 1991;48:340-347.
41. Hogarty GE, McEvoy JP, Munetz M, et al. Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Arch Gen Psychiatry 1988;45:797-805.
42. Johnston-Cronk K, Marder SR, Wirshing WC, et al. Prediction of schizophrenic relapse using prodromal symptoms. Schizophrenia Res 1993;9:259.
43. Johnstone EC, Frith CD, Gold A, Crow TJ. The outcome of severe acute schizophrenic illnesses after one year. Br J Psychiatry 1979;134:28-33.
44. Jolley AG, Hirsch SR, Morrison E, McRink A, Wilson L. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: Clinical and social outcome at two years. Br Med J 1990;301:837-842.
45. Kalinowsky LB. Appraisal of the "tranquilizers" and their influence on other somatic treatments in psychiatry. Am J Psychiatry 1958;115:294-300.
46. Kane J, Honigfeld G, Singer J and Meltzer H. Clozapine for the treatment-resistant schizo-phrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796.
47. Kane JM, Davis JM, Schooler NR, Marder SR, Brauzer B, Casey DE. A one-year comparison of four dosages of haloperidol decanoate. Schizophrenia Res 1993;9:239-240.
48. Kane JM, Lieberman JA: Maintenance pharmacotherapy in schizophrenia. In: Meltzer HY, ed., Psychopharmacology, The Third Generation of Progress: The Emergence of Molecular Biology and Biological Psychiatry. New York: Raven Press, 1987;1103-1109.
49. Kane JM, Rifkin A, Woerner M, et al. Low-dose neuroleptic treatment of outpatient schizophrenics: I. Preliminary results for relapse rates. Arch Gen Psychiatry 1983;40:893-896.
50. Keckica WA. Violence as a manifestation of akathisia. J Am Med Assoc 1978;240:2185.
51. Lehman AF, Steinwachs DM, and the Co-Investigators of the PORT Project. At Issue: Translating research into practice: The schizophrenia patient outcomes research team (PORT) treatment recommendations. Schizophrenia Bull 1998;24:1-10.
52. Levinson DF, Simpson GM, Singh H, et al.: Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment. Arch Gen Psychiatry 1990;47:761-768.
53. Liberman RP, Mueser KT, Wallace CJ. Social skills training for schizophrenic individuals at risk for relapse. Am J Psychiatry 1986;143:523-526.
54. Lieberman JA, Kane JM, Sarantakos S, et al. Prediction of relapse in schizophrenia. Arch Gen Psychiatry 1987;44:597-603.
55. Lindstrom E, Eriksson B, Hellgren A, von Knorring L, Eberhard G. Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clinical Therapeutics 1995;17:402-412.
56. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835.
57. Marder SR, Van Putten T, Mintz J, Lebell M, McKenzie J, May PRA. Low-and conventional-dose maintenance therapy with fluphenazine decanoate: Two-year outcome. Arch Gen Psychiatry 1987;44:518-521.
58. Marder SR, Wirshing WC, Van Putten T, et al. Fluphenazine vs. placebo supplementation for prodromal signs of relapse in schizophrenia. Arch Gen Psychiatry 1994;51:280-287.
59. McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia. Arch Gen Psychiatry 1991;48:739-745.
60. Meltzer HY, Bastani B, Young Kwon K, et al. A prospective study of clozapine in treatment-resistant schizophrenia patients. Psychopharmacology 1989;99:S68-S72.
61. Meltzer HY, Burnett S, Bastani B, Ramirez LF. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Comm Psychiatry 1990;41:892-897.
62. Meltzer HY. Dopamine and negative symptoms in schizophrenics: Critique of the type I-type II hypothesis. In: M. Alpert, ed. Controversies in schizophrenia: Changes and constancies. New York: Guilford Press, 1985;110-136.
63. Müller P, Bandelow B, Gaebel W, et al. Intermittent medication, coping and psychotherapy interactions in relapse prevention and course modification. Br J Psychiatry 1992;161(Suppl 18):140-144.
64. Newcomer JW, Faustman WO, Yeh W, Csernansky JG. Distinguishing depression and negative symptoms in unmedicated patients with schizophrenia. Psychiatry Res 1990;243-250.
65. Newcomer JW, Miller LS, Faustman WO, Wetzel MW, Vogler GP, Csernansky JG. Correlations between akathisia and residual psychopathology: A by-product of neuroleptic-induced dysphoria. Br J Psychiatry 1993; in press.
66. Prosser ES, Csernansky JG, Kaplan J, Thiemann S, Becker TJ, Hollister LE. Depression, parkinsonian symptoms, and negative symptoms in schizophrenics treated with neuroleptics. J Nerv Ment Dis 1987;175:100-105.
67. Rosenheck R, Dunn L, Peszke M, et al. Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Am J Psychiatry 1999;156:88-93.
68. Schooler NR, Keith SJ, Severe JB, et al. Acute treatment response and short term outcome in schizophrenia: first results of the NIMH treatment strategies in schizophrenia study, Treatment Strategies in Schizophrenia Collaborative Study Group. Psychopharmacol Bull 1989;25:331-335.
69. Schooler NR, Keith SJ, Severe JB, Matthews SM. Treatment strategies in schizophrenia: effects of dosage reduction and family management on outcome. Schizophrenia Res 1993;9:260.
70. Schooler NR. Maintenance medication for schizophrenia: Strategies for dose reduction. Schizophrenia Bull 1991;17:311-324.
71. Singh MM. Dysphoric response to neuroleptic treatment in schizophrenia and its prognostic significance. Dis Nerv Syst 1976;37:191-196.
72. Siris SG, Adan F, Cohen M, Mandeli J, Aronson A, Casey E. Postpsychotic depression and negative symptoms: An investigation of syndromal overlap. Am J Psychiatry 1988;145:1532-1537.
73. Tarrier N, Barrowclough C, Vaughn C, Bamrah JS, Porceddu K, Watts S, Freeman H. The community management of schizophrenia. The controlled trial of a behavioral intervention with families to reduce relapse. Br J Psychiatry 1988;153:532-542.
74. Tollefson GD, Beasley CM Jr, et al. Olanzapine versus haloperidol in the treatment of
schizophrenia and schizoaffective and schizophreniform disorders: results of an international
collaborative trial. Am J Psychiatry 1997;154:457-65.
75. Tollefson GD, Sanger TM, Beasley CM, Tran PV. A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biol Psychiatry 1998;43:803-10.
76. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C Jr,
Tollefson GD. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacology 1997;17:407-18.
77. Tollefson GD, Sanger JM, Lu Y, Thieme ME. Depressive signs and symptoms in schizophrenia: A prospective trial of olanzapine and haloperidol. Arch Gen Psychiatry 1988;55:250-258.
78. Van Putten T, Crumpton E, Yale C. Drug refusal in schizophrenia and the wish to be crazy. Arch Gen Psychiatry 1976;33:1443-1446.
79. Van Putten T, Marder SR, Mintz J, Poland RE. Haloperidol plasma levels and clinical response: A therapeutic window relationship. Am J Psychiatry 1992;149:500-505.
80. Van Putten T, Marder SR, Mintz J. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry 1990;47:754-758.
81. Van Putten T, May PRA, Marder SR. Akathisia with haloperidol and thiothixene. Arch Gen Psychiatry 1984;41:1036-1039.
82. Van Putten T, May PRA. Subjective response as a predictor of outcome in pharmacotherapy. Arch Gen Psychiatry 1978;35:477-480.
83. Van Putten T. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 1974;31:67-72.
84. van Kammen DP. The biochemical basis of relapse and drug response in schizophrenia: Review and hypothesis. Psychol Med 1991;21:881-895.
85. Vaughn CE, Leff JP. The influence of family and social factors on the course of psychiatric illness: A comparison of schizophrenic and depressed neurotic patients. Br J Psychiatry 1976;129:125-137.
86. Wolkowitz OM, Pickar D, Doran AR, Breier A, Tarell J, Paul SM. Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia. Am J Psychiatry 1986;143:855-87.
published 2000